Publication | Closed Access
Phase 2 trial results with the novel neurokinin‐1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy‐induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
29
Citations
8
References
2009
Year
Casopitant plus ond/dex was more effective than ond/dex alone for the prevention of CINV.
| Year | Citations | |
|---|---|---|
Page 1
Page 1